Related Experiment Video

Updated: May 27, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Beta-blocker therapy for hypertension

S J Reeder1, R L Hoffmann

  • 1Villanova University School of Nursing, Villanova, PA, USA.

Dimensions of Critical Care Nursing : DCCN
|November 15, 2011
PubMed

Insights

Hypertension increases the risk of serious diseases. Beta-blocker medications effectively lower blood pressure and prevent associated complications, aiding critical care decisions.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Hypertension is a significant risk factor for severe health conditions, including heart disease, myocardial infarction, renal failure, and stroke.
  • Effective management of hypertension is crucial for mitigating its detrimental effects and preventing secondary complications.

Purpose of the Study:

  • To detail the pathophysiology and theories behind primary hypertension.
  • To outline the complications associated with hypertension.
  • To provide critical care nurses with information on beta-blocker therapy, including pharmacodynamics, recent research, and clinical decision-making.

Main Methods:

  • Literature review on hypertension pathophysiology and complications.
  • Analysis of beta-blocker mechanisms of action and clinical research.
  • Focus on critical care nursing implications for medication management.

Main Results:

  • Beta-blockers are effective in reducing blood pressure.
  • These medications help prevent adverse outcomes like ventricular remodeling, endothelial dysfunction, and renal insufficiency.
  • Understanding beta-blocker pharmacodynamics is key for critical care decision-making.

Conclusions:

  • Beta-blocker therapy is a vital component in managing hypertension and its complications.
  • Critical care nurses require updated knowledge on beta-blockers for optimal patient care.
  • Further research into beta-blocker therapy can enhance treatment strategies for hypertensive patients.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...